The INVES BIOFARM research team is proud to announce our involvement in another project of excellence in innovation.
Our primary goal is the development of a highly effective and safe product for the treatment of knee joint lesions (or articular injuries). We aim to address osteoarticular pathologies through an innovative solution that offers regenerative benefits.
The core of this innovation lies in the implementation of an advanced encapsulation method to incorporate new technologies into the final formulation. This approach guarantees the stability, efficacy, and controlled release of the active principles, thereby maximizing their therapeutic potential.
The project is supported by a high-level scientific and technological consortium, composed of:
Inves Biofarm (Coordinator) Leitat (Technological Center) VHIR (Vall d’Hebron Research Institute)
This collaboration is based on a long and fruitful track record of joint success, ensuring the integration of expertise in research, technological development, and clinical application.The INVES BIOFARM research team is proud to announce our involvement in another project of excellence in innovation.
Our primary goal is the development of a highly effective and safe product for the treatment of knee joint lesions (or articular injuries). We aim to address osteoarticular pathologies through an innovative solution that offers regenerative benefits.
The core of this innovation lies in the implementation of an advanced encapsulation method to incorporate new technologies into the final formulation. This approach guarantees the stability, efficacy, and controlled release of the active principles, thereby maximizing their therapeutic potential.
The project is supported by a high-level scientific and technological consortium, composed of:
Inves Biofarm (Coordinator) Leitat (Technological Center) VHIR (Vall d’Hebron Research Institute)
This collaboration is based on a long and fruitful track record of joint success, ensuring the integration of expertise in research, technological development, and clinical application.
This project is part of the PCPP 2023 program and is funded under reference CPP2023-010897, with the support of:
